TCRR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 geg. 2023 @ 23:00):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer...

Stats
Šios dienos apimtis	3.75M
Vidutinė apimtis	325 040
Rinkos kapitalizacija	58.11M
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.352
ATR14	$0.105 (7.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-01	Tang Kevin C	Sell	4 394 800	Common Stock
2023-06-01	Ubs Oncology Impact Fund L.p.	Sell	3 370 982	Common Stock
2023-06-01	Mpm Sunstates Fund, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Mpm Bioventures 2014, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Gadicke Ansbert	Sell	3 370 982	Common Stock

INSIDER POWER
-89.64
Last 99 transactions
Buy: 1 629 400 \| Sell: 23 030 678

Tūris Koreliacija

Ilgas: 0.06 (neutral)

Trumpas: -0.70 (moderate negative)

Signal:(27.338) Neutral

TCR2 Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RMRM	0.89
GAINL	0.889
APOP	0.884
PAIC	0.864
TDAC	0.851
SPRT	0.842
ISNS	0.833
TLGT	0.82
SVAC	0.816

10 Labiausiai neigiamai susiję koreliacijos
BOCH	-0.936
BNIXU	-0.929
MMAC	-0.891
NETE	-0.87
SHSP	-0.865
AMRB	-0.841
DSPG	-0.816

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

TCR2 Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.24
( neutral )

0.47
( neutral )

0.70
( moderate )

0.71
( moderate )

-0.81
( strong negative )

-0.30
( neutral )

TCR2 Therapeutics Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-3.93

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-3.93

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.57

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.40

Financial Reports:

No articles found.

TCR2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.